- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00140504
Preventing Adverse Drug Events With PatientSite
February 24, 2013 updated by: Saul N. Weingart, MD, PhD, Dana-Farber Cancer Institute
This is a study to better understand the nature and extent of adverse drug events (ADEs), defined as injuries due to prescription medications, in primary care.
We will study whether PatientSite (an internet-based communication program for patients and health care providers) can improve clinicians' ability to detect adverse drug events among primary care patients and to mitigate the consequences by sending electronic queries to patients after they receive new medication prescriptions.
Study Overview
Detailed Description
- A drug safety module called MedCheck was developed for PatientSite. This allows physicians to query patients automatically 10 days after they receive a new prescription asking them questions about their new prescription. In this study new enhancements will be tested.
- Participants will be assigned at random to the intervention group or control group. The intervention group will receive a single electronic PatientSite message asking them questions about the new prescription which is then forwarded to their physician. The control group will receive a generic message about medication safety.
- To identify adverse drug events, a telephone survey and medical record review will be conducted of patients in the intervention group and controls.
- This study will run for 12 months.
Study Type
Interventional
Enrollment (Anticipated)
800
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult patients >18
- Patients that receive a new prescription
- Proficient in spoken and written english
Exclusion Criteria:
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MedCheck
Electronic medication safety queries via PatientSite portal
|
Participants selected at random will receive one email message asking them questions about their prescription which will be forwarded to their physician
|
No Intervention: Usual care
No electronic medication safety messages via PatientSite portal
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To prevent adverse drug events with PatientSite.
Time Frame: 3 years
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Improve patient satisfaction
Time Frame: 3 years
|
3 years
|
better utilization of services
Time Frame: 3 years
|
3 years
|
improve patient-clinician communication
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Saul N Weingart, MD, PhD, Dana-Farber Cancer Institute
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2003
Primary Completion (Actual)
December 1, 2004
Study Completion (Actual)
December 1, 2004
Study Registration Dates
First Submitted
August 30, 2005
First Submitted That Met QC Criteria
August 31, 2005
First Posted (Estimate)
September 1, 2005
Study Record Updates
Last Update Posted (Estimate)
February 26, 2013
Last Update Submitted That Met QC Criteria
February 24, 2013
Last Verified
February 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 05-061
- Weingart - K08HS11644
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adverse Drug Event
-
University of RochesterAgency for Healthcare Research and Quality (AHRQ)CompletedAdverse Drug Event, Potential Adverse Drug Event, and Quality MeasuresUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Vancouver Coastal Health; Ministry...Not yet recruitingAdverse Drug Event | Adverse Drug Reaction
-
University of PittsburghRANDCompletedAdverse Drug EventsUnited States
-
US Department of Veterans AffairsCompletedAdverse Drug EventsUnited States
-
Westview Physician CollaborativeCompletedAdverse Drug EventsCanada
-
Ottawa Hospital Research InstituteMcGill University; Canadian Institutes of Health Research (CIHR)CompletedAdverse Drug EventsCanada
-
Intermountain Health Care, Inc.Completed
-
Cedars-Sinai Medical CenterNational Institutes of Health (NIH); National Institute on Aging (NIA)Completed
-
University of Massachusetts, WorcesterAgency for Healthcare Research and Quality (AHRQ); Baycrest Centre for Geriatric...WithdrawnAdverse Drug Events
-
Indiana UniversityBrigham and Women's HospitalCompleted
Clinical Trials on Medcheck message
-
Washington University School of MedicineEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingCovid19 | Intellectual Disability | Developmental Disability | Child Development DisorderUnited States
-
Children's Hospital Medical Center, CincinnatiCompletedEffect of Varied Outreach Methods on Appointment Scheduling and Appointment Completion Using MyChartHealth Care UtilizationUnited States
-
University of North Carolina, Chapel HillWellcome TrustCompletedHeart Diseases | Obesity | CancerUnited States
-
Harvard UniversityCompletedIntention | Exploratory BehaviorUnited States
-
Imperial College LondonNHS England (NHSE/I) LondonCompleted
-
University of PennsylvaniaCompleted
-
John Paul II University of Applied Sciences in...CompletedCommunication | Activity, Motor | MusclePoland
-
Abramson Cancer Center at Penn MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH)Active, not recruiting
-
University of RochesterNational Cancer Institute (NCI)Completed